Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors
Keywords:
Bone neoplasms, Radionuclide imaging, Predictive value of tests, Alkaline phosphatase, Collagen type IAbstract
CONTEXT AND OBJECTIVE: Cross-linked N-telopeptides of type I collagen (NTx) increase in concentration in situations in which bone resorption is increased, such as osteoporosis and bone metastasis (BM). We aimed to evaluate the serum concentrations of NTx in a sample of patients with several types of solid tumors. DESIGN AND SETTING: Cross-sectional analytical study with a control group in a tertiary public hospital. METHODS: We performed the quantitative enzyme-linked immunosorbent assay (ELISA) on serum NTx levels in 19 subjects without a history of cancer and 62 patients with various solid tumors who had been referred for a bone scan. Three experienced analysts read all bone scans. RESULTS: The serum NTx levels in patients with cancer and BM, with cancer but without BM and without cancer were 46.77 ± 2.58, 32.85 ± 2.05 and 22.32 ± 2.90 respectively (P < 0.0001). We did not find any significant correlations of serum NTx with age, gender, history of bone pain, tumor type and bone alkaline phosphatase levels. We found a significant correlation between serum NTx and alkaline phosphatase levels (R2 = 0.08; P = 0.022). CONCLUSIONS: Serum NTx levels are significantly higher in patients with solid tumors and bone metastases than they are in patients without bone metastases and in normal controls.
Downloads
References
Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol. 2004;2(3):205-13; discussion 213-4, 216-7, 219-20.
Lipton A. Bisphosphonates and metastatic breast carcinoma. Cancer. 2003;97(3 Suppl):848-53.
Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 upda- te on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042-57.
Green JR. Skeletal complications of prostate cancer: pathophysiology and therapeutic po- tential of bisphosphonates. Acta Oncol. 2005;44(3):282-92.
Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-82.
Price CP. Multiple forms of human serum alkaline phosphatase: detection and quantitation. Ann Clin Biochem. 1993;30(Pt 4):355-72.
Kanakis I, Nikolaou M, Pectasides D, Kiamouris C, Karamanos NK. Determination and bio- logical relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer. J Pharm Biomed Anal. 2004;34(4):827- 32.
Amico S, Liehn JC, Desoize B, Larbre H, Deltour G, Valeyre J. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma. Clin Nucl Med. 1991;16(9):643-8.
Wolff JM, Ittel T, Borchers H, Brauers A, Jakse G. Efficacy of skeletal alkaline phosphatase and prostate-specific antigen in the diagnosis of bone metastasis in cancer of the prostate. Urol Int. 1998;61(1):12-6.
Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res. 2004;24(5B):3193-201.
Clemons M, Cole DE, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat. 2006;97(1):81-90.
Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol. 2006;24(30):4895-900.
Pectasides D, Nikolaou M, Farmakis D, et al. Clinical value of bone remodelling ma- rkers in patients with bone metastases treated with zoledronic acid. Anticancer Res. 2005;25(2B):1457-63.
Pectasides D, Farmakis D, Nikolaou M, et al. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer. J Pharm Biomed Anal. 2005;37(1):171-6.
Koizumi M, Takahashi S, Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res. 2003;23(5b):4095-9.
Schindler F, Lajolo PP, Pinczowski H, et al. Bone and total alkaline phosphatase for scre- ening skeletal metastasis in patients with solid tumours. Eur J Cancer Care (Engl). 2008;17(2):152-6.
Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decre- ases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20(Suppl 2):45-54.
Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003;89(11):2031-7.
Peters JL, Fairney A, Kyd P, et al. Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis. 2001;4(3):161-6.
